Dr. Elizabeth Mittendorf, MD

Dr. Mittendorf practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Mittendorf's NPI, 1831288596, was assigned on October 12, 2006. Dr. Mittendorf graduated from Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University in 1996. Dr. Mittendorf holds Massachusetts license 273553.

Dr. Mittendorf's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Mittendorf's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Mittendorf is also affiliated with Brigham and Women's Hospital. The medical group on file is Brigham and Women's Hospital. Dmand AI also links Dr. Mittendorf to 2 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mittendorf practices, 4 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Mittendorf's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dmand AI has Dr. Mittendorf's licenses on file in 2 states: Massachusetts and Texas.

CMS data shows 237 Medicare services from Dr. Mittendorf across 7 procedure codes in 2024, for 79 Medicare patients. Medicare paid $46,613 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 79 Medicare patients who saw Dr. Mittendorf in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have cancer, and 71% have high cholesterol. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mittendorf's median patient age at 64, with 99% women.

Dr. Mittendorf accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 22 procedures of mastectomy by Dr. Mittendorf, more than 80% of the clinicians it reports for that procedure.

Dmand AI links 306 papers to Dr. Mittendorf, published from 2007 to 2025. 2024 was the busiest year, with 29. The most frequent topics are Breast Neoplasms, Neoadjuvant Therapy and Antineoplastic Combined Chemotherapy Protocols. Dr. Mittendorf has published most often in Ann Surg Oncol. Dr. Mittendorf's most frequent co-authors are Tari A. King, MD, Sara Michell Tolaney, MD and Isabelle Bedrosian, MD.

Dmand AI links Dr. Mittendorf to 9 clinical trials, 4 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Intraductal, Noninfiltrating. Alliance for Clinical Trials in Oncology sponsors the most, 2.

CMS Open Payments shows 72 general payments to Dr. Mittendorf from 9 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 43% of the total. Merck Sharp & Dohme Corporation paid the most, $64,932. It also lists 14 research payments totaling $9,585 from 2020 to 2025.

Dr. Mittendorf graduated from Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University in 1996.